Global Fatty Liver Disease Drugs Market: (2017-2022)

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast

(2017-2022) • By Type- ALD and NAFLD • ALD Stages - Alcoholic Steatosis and Alcoholic Steatohepatitis • NAFLD Stages - Non Alcoholic Steatosis and NASH • By Region- North America, Europe, Asia Pacific and ROW • By Country - United States, Canada, United Kingdom, Germany, France, India, Japan, China, Saudi Arabia, South Africa, Brazil.

July 2017

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)  By Type

 Global Coverage  Scope of the Study  g

 By NAFLD Stages

 Regional Coverage

 By ALD Stages

 Country Coverage

Global Coverage  Fatty Liver Disease Market – By Value (2012-2022)  Breakdown-By Type (2012-2021)



Region (North America, Europe, APAC and ROW )



Country (U.S., Canada, China, Japan, India , Germany, France, United Kingdom, Saudi Arabia, South Africa, Brazil,)

 By Type of Drugs

Regional Coverage  North America  Europe  Asia Pacific  ROW

Country Coverage

Company Coverage

 U.S.  Canada

 Pfizer

 Germany

 Conatus

•

ALD

 France

 Novartis

•

NAFLD

 U.K.

 Intercept pharmaceuticals

 China

 Allergan

 Japan

 Immuron

 India

 Takeda

 Brazil

 Gilead sciences

 South Africa

 Genfitt

 Breakdown –By NAFLD Stages (20122022): (Steatosis , NASH)  Breakdown –By ALD Stages (20122022): (Steatosis, Alcohol Hepatitis)  Breakdown by ALD drugs(20122022): (Opoid Antagonist

 Fatty Liver Disease Market - By Value (2012-2016)  Fatty Liver Disease Market – By Value (2017-2022)

 South Arabia  Fatty Liver Disease Market – By

,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor)  Breakdown By NAFLD Drug(2012-

Type (2012-2022)  Fatty Liver Disease Market –By ALD Drugs ( 2012-2022)

2022) : (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)

 Fatty Liver Disease Market- By

NAFLD Drug

 Product Benchmarking  Fatty Liver Disease Market : By Value (2012-2022)

  Product Sales Benchmarking  Business Sales Overview 

 Fatty Liver Disease Market : By

 Overview& Recent  Business Product Launches

Type , By Value (2012-2022)

 Approvals Product Launches & Recent  Approvals Merger & Acquisition  Merger & Acquisition 2

Table of Content S. No

Particulars

Page No.

1.

Research Methodology

22

2.

Executive Summary

23

3.

Strategic Recommendation

24

3.1

Focus on Asia Region

25

3.2

Focus on drug development for NASH and Alcohol Hepatitis

26

3.3

Focus on early Stage detection of Alcohol and Non Alcoholic Steatosis

27

4.

Fatty Liver Market Outlook

28

5.

Global Fatty Liver Disease Market: Growth and Forecast

36

6

5.1

By Value (2012-2016)

37

5.2

By Value (2017-2022)

38

Global Fatty Liver Disease –By Type 6.1

6.2

Global Fatty Liver Disease Market -By Type (Alcoholic Fatty Liver Disease (ALD), Non Alcoholic Fatty Liver Disease (NAFLD)): Breakdown(%)

39 39

6.1.1

Global Fatty Liver Disease Market-By Type,2016 (%)

40

6.1.2

Global Fatty Liver Disease Market-By Type,2022 (%)

41

Global Fatty Liver Disease –By Type, By Value

42

6.2.1

Global Alcoholic Fatty Liver Disease Market

42

6.2.1.1

42

By Value (2012-2022)

3

Table of Content S. No

Particulars 6.2.2

7.

Global Non Alcoholic Fatty Liver Disease Market

44

6.2.2.1

44

7.2

47

7.1.1

Global Alcoholic Fatty Liver Disease Market -By Stages, 2016 (%)

48

7.1.2

Global Alcoholic Fatty Liver Disease Market -By Stages, 2022 (%)

49

Global Alcoholic Fatty Liver Disease Market -By Stages, By Value

50

7.2.1

Global Alcoholic Steatosis Market

50

7.2.1.1

50

By Value (2012-2022)

Global Alcoholic Steatohepatitis Market 7.2.2.1

By Value (2012-2022)

Global Non Alcoholic Fatty Liver Disease Market–By Stages 8.1

47

Global Alcoholic Fatty Liver Disease Market -By Stages (Alcoholic Steatosis and Alcoholic Steatohepatitis): Breakdown(%)

7.2.2

8.

By Value (2012-2022)

Global Alcoholic Fatty Liver Disease Market –By Stages

7.1

Page No.

Global Non Alcoholic Fatty Liver Disease Market -By Stages (Non Alcoholic Steatosis and Non Alcoholic Steatohepatitis ) : Breakdown(%)

52 52 54 54

8.1.1

Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2016(%)

55

8.2.1

Global Non Alcoholic Fatty Liver Disease Market -By Stages , 2022 (%)

56

4

Table of Content S. No

Particulars 8.2

Global Non Alcoholic Fatty Liver Disease Market -By Stages , By Value

57

8.2.1

Global Non Alcoholic Steatosis Market

57

8.2.1.1

By Value (2012-2022)

57

Global Non Alcoholic Steatohepatitis Market

58

By Value (2012-2022)

58

8.2.2

8.2.2.1 9.

Global Alcoholic Fatty Liver Disease Market –By Drugs 9.1

9.2

Page No.

Global Alcoholic Fatty Liver Disease Market -By Drugs (Opoid Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) : Breakdown(%)

61 61

9.1.1

Global Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%)

62

9.1.2

Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%)

63

Global Alcoholic Fatty Liver Disease Market -By Drugs , By Value

9.2.1

9.2.2

9.2.3

64

Global Opioid Antagonist Drug Market

64

By Value (2012-2022)

64

Global Pentoxifylline Drug Market

66

By Value (2012-2022)

66

Global Glucocorticoid Drug Market

67

By Value (2012-2022)

67

5

Table of Content S. No

Particulars 9.2.4

9.2.5

10.

Global Antioxidants Drug market

69

9.2.4.1

69

By Value (2012-2022)

Global Granulocyte colony stimulating factor Drug Market

71

9.2.5.1

71

By Value (2012-2022)

Global Non Alcoholic Fatty Liver Disease Market –By Drugs 10.1

10.2

Page No.

Global Non Alcoholic Fatty Liver Disease Market -By Drugs (Antioxidants, Thiazolidinedione, Biguanides, Lipid Lowering Agents, FXR Receptor Agonist, Elafibranor ) : Breakdown(%)

73 73

10.1.1

Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2016(%)

74

10.2.1

Global Non Alcoholic Fatty Liver Disease Market -By Drugs , 2022 (%)

75

Global Non Alcoholic Fatty Liver Disease Market -By Drugs , By Value 10.2.1

10.2.2

10.2.3

76

Global Antioxidants Drug Market

76

10.2.1.1

76

By Value (2012-2022)

Global Thiazolidinedione Drug Market

78

10.2.2.1

78

By Value (2012-2022)

Global Biguanides Drug Market

80

10.2.3.1

80

By Value (2012-2022)

6

Table of Content S. No

Particulars 10.2.4

10.2.5

10.2.6

Page No.

Global Hypolipidemic Agents Drug market

82

10.2.4.1

82

By Value (2012-2022)

Global FXR Receptor Agonist Drug Market

84

10.2.5.1

84

By Value (2012-2022)

Global Elafibranor Drug Market

86

10.2.6.1

86

By Value (2012-2022)

11.

Global Fatty Liver Disease Market – Pipeline Analysis (By developer, Phase and indication)

88

12.

Global Fatty Liver Disease Market – Regional Analysis

93

12.1

93

13.

Global Fatty Liver Disease Market -By Regional : Breakdown(%) 12.1.1

Global Fatty Liver Disease Market -By Region, 2016(%)

94

12.1.2

Global Fatty Liver Disease Market -By Region, 2022 (%)

95

North America Fatty liver Disease Market

96

13.1

By Value (2012-2022)

97

13.2

North America Fatty liver Disease Market – By Type , By Value

100

13.3

North America Fatty liver Disease Market – By ALD Drug , By Value

102

7

Table of Content S. No

Particulars 13.4

14.

North America Fatty liver Disease Market – By NAFLD Drug , By Value

North America Fatty Liver Disease Market –By Country Analysis

105

North America Fatty Liver Disease Market –By Country ,2012-2016(%)

106

14.2

North America Fatty Liver Disease Market –By Country ,2017E-2022F(%)

106

14.3

United States Fatty Liver Disease Market – By Value(2012-2022)

107

14.4

United States Fatty Liver Disease Market By Type, By Value

Canada Fatty Liver Disease Market – By Value(2012-2022) 14.4.1

16.

104

14.1

14.3.1

15.

Page No.

Canada Fatty Liver Disease Market By Type, By Value

109 110 111

Asia Pacific Fatty liver Disease Market

113

15.1

By Value (2012-2022)

114

15.2

Asia Pacific Fatty liver Disease Market – By Type , By Value

117

15.3

Asia Pacific Fatty liver Disease Market – By ALD Drug , By Value

119

15.4

Asia Pacific Fatty liver Disease Market – By NAFLD Drug , By Value

121

Asia Pacific Fatty Liver Disease Market –By Country Analysis

122

16.1

Asia Pacific Fatty Liver Disease Market –By Country ,2012-2016(%)

123

16.2

Asia Pacific Fatty Liver Disease Market –By Country ,2017E-2022F(%)

123

8

Table of Content S. No

Particulars 16.3

India Fatty Liver Disease Market – By Value(2012-2022) 16.3.1

126

China Fatty Liver Disease Market – By Value(2012-2022)

127

16.5

Japan Fatty Liver Disease Market – By Value(2012-2022)

129

16.6

18.

124

16.4

16.5.1

17.

India Fatty Liver Disease Market By Type, By Value

Page No.

Japan Fatty Liver Disease Market By Type, By Value

Rest of Asia Fatty Liver Disease Market-By Value(2012-2022)

130 131

Europe Pacific Fatty liver Disease Market

132

17.1

By Value (2012-2022)

133

17.2

Europe Fatty liver Disease Market – By Type , By Value

137

17.3

Europe Fatty liver Disease Market – By ALD Drug , By Value

139

17.4

Europe Fatty liver Disease Market – By NAFLD Drug , By Value

141

Europe Fatty Liver Disease Market –By Country Analysis

142

18.1

Europe Fatty Liver Disease Market –By Country ,2012-2016(%)

143

18.2

Europe Fatty Liver Disease Market –By Country ,2017E-2022F(%)

143

9

Table of Content S. No

Particulars 18.3

United Kingdom Fatty Liver Disease Market – By Value(2012-2022) 18.3.1

18.4

Germany Fatty Liver Disease Market – By Value(2012-2022) 18.4.1

18.5

19.

20.

Germany Fatty Liver Disease Market By Type, By Value

France Fatty Liver Disease Market – By Value(2012-2022) 18.5.1

18.6

United Kingdom Fatty Liver Disease Market By Type, By Value

France Fatty Liver Disease Market By Type, By Value

Rest of Europe Fatty Liver Disease Market-By Value(2012-2022)

Page No. 144 145 147 149 150 151 152

Rest of World Fatty liver Disease Market

153

19.1

By Value (2012-2022)

154

19.2

Rest of World Fatty liver Disease Market – By Type , By Value

156

19.3

Rest of World Fatty liver Disease Market – By ALD Drug , By Value

158

19.4

Rest of World Fatty liver Disease Market – By NAFLD Drug , By Value

160

Rest of World Fatty Liver Disease Market –By Country Analysis

161

20.1

Rest of World Fatty Liver Disease Market –By Country ,2012-2016(%)

162

20.2

Rest of World Fatty Liver Disease Market –By Country ,2017E-2022F(%)

162

10

Table of Content S. No

Particulars 20.3

Saudi Arabia Fatty Liver Disease Market – By Value(2012-2022) 20.3.1

20.4

South Africa Fatty Liver Disease Market – By Value(2012-2022) 20.4.1

20.5

21.

South Africa Fatty Liver Disease Market By Type, By Value

Brazil Fatty Liver Disease Market – By Value(2012-2022) 20.5.1

20.6

Saudi Arabia Fatty Liver Disease Market By Type, By Value

Brazil Fatty Liver Disease Market By Type, By Value

Others Fatty Liver Disease Market-By Value(2012-2022)

Page No. 163 164 166 168 169 170 171

Market Dynamics

172

21.1

Drivers

173

21.2

Challenges

177

22.

Market Trends

180

23.

Policy and Regulations

182

24.

Porter Five Force

190

25.

SWOT Analysis

192

26.

Company Profiling

194

11

Table of Content S. No

27.

Particulars

Page No.

26.1

Pfizer

195

26.2

Conatus Pharmaceuticals

197

26.3

Novartis

198

26.4

Intercept Pharmaceuticals

200

26.5

Allergan

201

26.6

Immuron

202

26.7

Takeda

203

26.8

Gilead Sciences

205

26.9

Genfit

207

About Us

208

12

List of Figures Figure No.

Figure Title

Page No.

Figure 1:

History of Fatty Liver Disease

31

Figure 2:

Therapeutic Algorithm for Management of Alcoholic Hepatitis

32

Figure 3:

Treatment Algorithm of NAFLD

35

Figure 4:

Global Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Million)

37

Figure 5:

Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million)

38

Figure 6:

Global Fatty Liver Disease Market Size, By Type, 2016 (%)

40

Figure 7:

Global Fatty Liver Disease Market Size, By Type, 2022F (%)

41

Figure 8:

Global Alcoholic Fatty liver Market Service Market, By Value, 2012-2016 (USD Billion)

42

Figure 9:

Global Alcoholic Fatty liver Market Service Market, By Value, Forecast, 2017E-2022F (USD Billion)

42

Figure 10:

Beer Consumption , Billion Liters , 2014

43

Figure 11:

Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, 2012-2016 (USD Billion)

44

Figure 12:

Global Non Alcoholic Fatty Liver Disease Treatment Market, By Value, Forecast, 2017E-2022F (USD Billion)

44

Figure 13:

Global Diabetic Population, By Region, 2015 (Million)

46

Figure 14:

Global Alcoholic Liver Disease Market Size, By Stage , 2016 (%)

48

Figure 15:

Global Alcoholic liver Disease Market Size, By Type, 2022F (%)

49

Figure 16:

Global Alcoholic Steatosis Treatment , By Value, 2012-2016 (USD Billion)

50

Figure 17:

Global Alcoholic Steatosis Treatment, By Value, Forecast, 2017E-2022F (USD Billion)

50

Figure 18:

World Alcohol Consumption , Liters per Capita, 2014-2016

51

Figure 19:

Global Alcoholic Staetohepatitis Market, By Value, 2012-2016 (USD Billion)

52

13

List of Figures Figure No.

Figure Title

Page No.

Figure 20:

Global Alcoholic Staetohepatitis Market, By Value, Forecast, 2017E-2022F (USD Billion)

52

Figure 21:

Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)

55

Figure 22:

Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2022F (%)

56

Figure 23:

Global Non Alcoholic Steatosis Treatment Market, By Value, 2012-2016 (USD Billion)

57

Figure 24:

Global Non Alcoholic Steatosis Treatment Market, By Value, Forecast, 2017E-2022F(USD Billion)

57

Figure 25:

Global NASH Market, By Value, 2012-2016 (USD Billion)

58

Figure 26:

Global NASH Market, By Value, Forecast, 2017E-2022F (USD Billion)

58

Figure 27:

Global Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)

62

Figure 28:

Global In-flight Catering Service Market Size, By Airline Type, 2022F (%)

63

Figure 29:

Global Opioid Antagonist Drug Market, By Value, 2012-2016 (USD Billion)

64

Figure 30:

Global Opioid Antagonist Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)

64

Figure 31:

Global Pentoxifylline Drug Market, By Value, 2012-2016 (USD Billion)

66

Figure 32:

Global Pentoxifylline Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)

66

Figure 33:

Global Glucocoticoid Drug Market, By Value, 2012-2016 (USD Billion)

67

Figure 34:

Global Glucocorticoid Drug Market, By Value Forecast, 2017E-2022F(USD Billion)

67

Figure 35:

Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)\

69

Figure 36:

Global Antioxidants Drug Market, By Value, , Forecast, 2017E-2022F(USD Billion)

69

Figure 37:

Global Granulocyte Colony Stimulating Factor Drug Market, By Value, 2012-2016 (USD Billion)

71

Figure 38:

Global Granulocyte Colony Stimulating Factor Drug Market , By Value, Forecast, 2017E-2022F(USD Billion)

71

Figure 39:

Global Non Alcoholic Fatty Liver Market Size, By Drug, 2016 (%)

74

14

List of Figures Figure No.

Figure Title

Page No.

Figure 40:

Global Non Alcoholic Fatty Liver Market Size, By Drug, 2022F (%)

75

Figure 41:

Global Antioxidants Drug Market, By Value, 2012-2016 (USD Billion)

76

Figure 42:

Global Antioxidants Drug Market, By Value, Forecast, 2017E-2022 (USD Billion)

76

Figure 43:

Global Thiazolidinedione Drug Market, By Value, 2012-2016 (USD Billion)

78

Figure 44:

Global Thiazolidinedione Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)

78

Figure 45:

Global Biguandies Drug Market, By Value, 2012-2016 (USD Billion)

80

Figure 46:

Global Biguandies Drug Market, By Value, Forecast, 2017E-2022F(USD Billion)

80

Figure 47:

Global Hypolipidemic Drug Market, By Value, 2012-2016 (USD Billion)

82

Figure 48:

Global Hypolipidemic Drug Market , By Value, Forecast, 2017E-2022F(USD Billion)

82

Figure 49:

Global FXR Receptor Agonist Drug Market, By Value, 2012-2016 (USD Billion)

84

Figure 50:

Global FXR Receptor Agonist Drug Market , By Value, Forecast, 2017E-2022F (USD Billion)

84

Figure 51:

Global Elafibranor Drug Market, By Value, 2012-2016 (USD Billion)

86

Figure 52:

Global Elafibranor Drug Market , By Value, Forecast, 2017E-2022F (USD Billion)

86

Figure 53:

Global Fatty Liver Disease Market Size and Share, By Region, 2016

94

Figure 54:

Global Fatty Liver Disease Market Size and Share, By Segments, 2022F

95

Figure 55:

North America Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

97

Figure 56:

North America Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

97

Figure 57:

North America Healthcare Expenditure, 2011-2014 (% of GDP)

98

Figure 58:

North America Population Age 15-64 2015 (% of Total)

98

Figure 59:

North America Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

100

Figure 60:

North America Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)

102

15

List of Figures Figure No.

Figure Title

Page No.

Figure 61:

North America Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)

104

Figure 62:

North America Fatty Liver Disease

106

Figure 63:

North America Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)

106

Figure 64:

United States Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

107

Figure 65:

United States Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

107

Figure 66:

Percentage of United states adults who had at least one heavy drinking day,2011-2015

108

Figure 67:

United States Alcohol Liters Per Capita Consumption, 2011-2015

108

Figure 68:

United States Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

109

Figure 69:

CanadaFatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

110

Figure 70:

Canada Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

110

Figure 71:

Canada Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

111

Figure 72:

Canada Alcohol Liters Per Capita Consumption, 2011-2015

112

Figure 73:

Prevalence of Obese and overweight Population , By Age,2014(% )

112

Figure 74:

Asia Pacific Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

114

Figure 75:

Asia PacificFatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

114

Figure 76:

Obesity Prevalence in Asian Countries, 2014 (%)

115

Figure 77:

Asia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

117

Figure 78:

Asia Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)

119

Figure 79:

Asia Pacific Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)

121

Figure 80:

Asia Pacific Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)

123

Market, Country Share, 2012-2016 (% of Total)

16

List of Figures Figure No.

Figure Title

Page No.

Figure 81:

Asia Pacific Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)

123

Figure 82:

India Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

124

Figure 83:

India Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

124

Figure 84:

Percentage of United states adults who had at least one heavy drinking day, 2011-2015

125

Figure 85:

India Alcohol Liter per capita Consumptions, 2015-2016

125

Figure 86:

India Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

126

Figure 87:

China Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

127

Figure 88:

China Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

127

Figure 89:

Health expenditure in China,2011-2015 (USD Billion)

128

Figure 90:

China Alcohol Liter per capita Consumptions,2015-2016

128

Figure 91:

Japan Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

129

Figure 92:

Japan Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

129

Figure 93:

Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

130

Figure 94:

Rest of Asia Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

131

Figure 95:

Rest of Asia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

131

Figure 96:

Europe Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

133

Figure 97:

Europe Fatty Liver Disease Market Size,

By Value, 2017E-2022F (USD Billion)

133

Figure 98:

Europe Diabetes Prevalence, By Country, 2015 (% of Population Aged 20 to 79)

134

Figure 99:

EU Health Expenditure Per Capita, 2011-2014 (USD)

135

Breakdown of Total Health Expenditure in Europe (%)

135

Figure 100:

17

List of Figures Figure No.

Figure Title

Page No.

Figure 101:

Europe Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

137

Figure 102:

Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion)

139

Figure 103:

Europe Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)

141

Figure 104:

Europe Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)

143

Figure 105:

Europe Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)

143

Figure 106:

United Kingdom Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

144

Figure 107:

United Kingdom Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

144

Figure 108:

United Kingdom Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

145

Figure 109:

Alcohol Related Disease Death, 2015

146

Figure 110:

Diabetes Prevalence in U.K. 2015

146

Figure 111:

Five Day Drinking Prevalence By Age, (%), 2014-2015

146

Figure 112:

Germany Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

147

Figure 113:

Germany Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

147

Figure 114:

Private Healthcare Spending in Germany, US Dollar/capita 2011 to 2015

148

Figure 115:

Diabetes Prevalence in 55-74 age people in Germany, Forecast 2030F.

148

Figure 116:

Alcohol Consumption per capita ,2012-2016 (liter) in Germany

148

Figure 117:

Germany Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million)

149

Figure 118:

France Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

150

Figure 119:

France Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

150

Figure 120:

France Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Million)

151

18

List of Figures Figure No.

Figure Title

Page No.

Figure 121:

Rest Of Europe Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

152

Figure 122:

Rest of Europe Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

152

Figure 123:

Rest of World Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

154

Figure 124:

Rest of World Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

154

Figure 125:

Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

156

Figure 126:

Rest of World Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

158

Figure 127:

Rest of world Fatty Liver Disease : By ALD Drug Type, By Value, 2012-2022 (USD Billion)

160

Figure 128:

Rest of World Fatty Liver Disease Market, Country Share, 2012-2016 (% of Total)

162

Figure 129:

Rest of World Fatty Liver Disease Market, Country Share, 2017-2022 (% of Total)

162

Figure 130:

Saudi Arabia Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

163

Figure 131:

Saudi Arabia Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

163

Figure 132:

Saudi Arabia Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

164

Figure 133:

Saudi Arabia Prevalence of Obesity Forecast 2022 (%)

165

Figure 134:

South Africa Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

166

Figure 135:

South Africa Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

166

Figure 136:

South Africa Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

168

Figure 137:

Brazil Fatty Liver Disease Market Size, By Value, 2012-2016 (USD Billion)

169

Figure 138:

Brazil Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

169

Figure 139:

Brazil Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion)

170

Figure 140:

Others Fatty Liver Disease Market Size, By Value, 2012-2016(USD Billion)

171

19

List of Figures Figure No.

Figure Title

Page No.

Figure 141:

Others Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Billion)

171

Figure 142:

Pfizer Segmental Breakup, 2016(%)

196

Figure 143:

Pfizer Sales, By Region, 2016 (%)

196

Figure 144:

Novartis Sales, By Segment 2015 (%)

199

Figure 145:

Novartis Sales, By Region,2015 (%)

199

Figure 146:

Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)

199

Figure 147:

Takeda Segmental Breakup

204

Figure 148:

Takeda Revenue, 2013-2016 (USD Million)

204

Figure 149:

Gilead Sciences Product Sales, 2016 (%)

206

Figure 150:

Gilead Sciences HCV Product Sales, 2014-2016

(USD Billion)

206

20

List of Tables Table No.

Table Title

Page No.

Table A:

Causes of NAFLD Infection

33

Table B:

Quantity of Alcohol in Standard Drink

51

Table C:

Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication

89

Table D:

Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication

90

Table E:

Non Alcoholic Fatty Liver Disease Market Analysis, By Drug, Developer, Phase, Indication

91

Table F:

NASH Multi Therapy Treatment Market Analysis, By Drug, Developer, Phase, Indication, Status

92

21

Research Methodology Research Definition Global Fatty Liver Disease Treatment Market Report comprises of the study of various aspects of Fatty Liver Market and forecast until 2022. Global Fatty Liver Disease Treatment Market has been segmented on basis of Types(Alcoholic and Non Alcoholic Fatty Liver); Alcoholic Fatty Liver By Stages

(Alcoholic Steatosis and

Alcoholic Steatohepatitis ), Non Alcoholic Fatty Liver Stages By Stages (Alcoholic Steatosis and Non Alcoholic

Steatohepatitis), By Region (North America, Europe, APAC, Middle East and ROW) and By Country (U.S., Canada, Germany, Russia, United Kingdom, China, India, Japan, Brazil, Mexico, Saudi Arabia, South Africa and UAE) Data Analysis and Interpretation Our historic market trend has been figured out by various paid databases which was further triangulated with inputs

and

insights

from

industry

experts,

companies

and

stakeholders,

through

primary

research

(manufacturers, marketing managers, others). Back-of-the-Envelope calculation for the market estimation has been made through proper understanding of the market as well as future business strategies of the companies operating in the market. The Report has covered

only two stages drug treatment for Alcoholic and Non

alcoholic fatty liver.

Azoth Analytics has conducted quantitative as well as qualitative research to gather market insights such as market sizing, market segmentation, recent trends and developments

and competitive landscape. Our team has conducted extensive primary surveys by

reaching out industry experts across the value chain of the global orthopeadic market.

Companies Contacted: St Stephen Hospital Delhi 22

Global Fatty Liver Disease Market Overview Global Fatty liver Disease market in the forecasted period will witness rapid growth owing to

several NASH Drug expected to enter the market in forecasted period.

Figure : Global Fatty Liver Disease Market Size, By Value, 2017E-2022F (USD Million) CAGR: xxxx%

2017E

2018F

2019F

2020F

2021F

2022F

Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx •

.

Xxxx Xxxx xxxx

23

Global Non Alcoholic Liver Disease Market-By Stages NASH treatment held the majority market share of approximately 81.67%, by value, in the year 2016.

Key Drivers

Figure : Global Non Alcoholic Liver Disease Treatment Market Size, By Type, 2016 (%)

Xxxxx

Non Alcoholic Steatosis

xxxxx

Non Alcoholic Steatohepatitis

Xxxxx xxxxx

Source: Azoth Analytics Estimates

24

North America Fatty Liver Disease Market Global Heart Valve Repair Devices Market,

By Value Figure : North America Fatty Liver Disease Market

Figure : North America Fatty Liver Disease Market

Size, By Value, 2012-2016(USD Billion)

Size, By Value, 2017E-2022F (USD Billion)

2012

2013

CAGR 2012-2015

CAGR 2016-2022

xxxx%

xxxx%

2014

2015

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates

Xxxx Xxxx •

.

Xxxx Xxxx xxxx

25

Japan Fatty Liver Disease Market, By Type Figure 93: Japan Fatty Liver Disease : By Type, By Value, 2012-2022 (USD Billion) CAGR 2012-2016 Alcoholic Fatty Liver Disease: xxxx% Non Alcoholic Fatty Liver Disease : xxxx%

2012

2013

2014

2015

CAGR 2017-2022 Alcoholic Fatty Liver Disease: xxxx% Non Alcoholic Fatty Liver Disease : xxxx%

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates

Xxxxx Xxxxx Xxxxx xxxxx

26

Europe Fatty Liver Disease Market, By NFALD Drug Figure : Europe Fatty Liver Disease : By NAFLD Drug Type, By Value, 2012-2022 (USD Billion) CAGR 2017-2022 Antioxidants: xxxx% Thiazlolidinedione: xxxx% Biguandies: xxxx% Hypolipidemic agents: xxxxx% FXR Receptor Agonist: xxxxx% Elafibranor: xxxx%

CAGR 2012-201 Antioxidants: xxxx% Thiazlolidinedione: xxxx% Biguandies: xxxx% HypolipidemicAgents: xxxx% FXR Receptor Agonist: xxxx% Elafibranor: xxxx %

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

Source: Azoth Analytics Estimates Xxxx Xxxx Xxxx

27

About Azoth Analytics Pvt Ltd.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

Related Reports: Global Vitreoretinal Surgery Devices Market (By Product, By End User, By Region, By Country): Opportunities and Forecast (2016-2021) – By Product (Vitrectomy Machines & Packs, Photocoagulation Surgery Devices, Illumination Devices, Others); By End User (Hospitals, Free Standing Ambulatory Surgery Center); By Region (North America, Europe, APAC, ROW); By Country (US, Canada, Mexico, UK, Germany, France, Japan, China,

India, Brazil, South Africa) Global Biomaterials Market (By Type, By Application, By Region): Opportunities and Forecasts (2016-2021) - (By Material Type – Polymer, Ceramic, Metal; By Application - Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, Europe, APAC, ROW; By Country – US, UK, Germany, Italy, Japan, China, India; Key Players – Strategy, Financial Performance)

Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.

28